Article
Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes.
Clinical pharmacology and therapeutics - 1 Apr 2005
Sugimoto Mitsushige, Furuta Takahisa, Shirai Naohito, Nakamura Akiko, Kajimura Masayoshi, Hishida Akira, Ohashi Kyoichi, Ishizaki Takashi
Abstract excerpt
BACKGROUND AND OBJECTIVE: A concomitant dosage regimen of a histamine 2 receptor antagonist with a proton pump inhibitor (PPI) effectively decreases the incidence of nocturnal acid breakthrough, which is one of the problems encountered when acid-related diseases are treated with a PPI alone. We compared the effectiveness of an increased dosage regimen of rabeprazole with that of a concomitant dosage regimen of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.